Overview

The purpose of this study is to validate the continuous patch monitoring system to evaluate cardiac arrhythmias in patients receiving drugs that can cause cardiac complications and compare the continuous patch system with standard electrocardiograms (ECGs).

Eligibility

Inclusion Criteria:

• Diagnosis of acute promyelocytic leukemia (APL) and being initiated on standard of care arsenic trioxide OR Diagnosis of solid tumor and being initiated on standard of care capecitabine (alone or as part of combination treatment) OR Diagnosis of solid tumor and being initiated on standard of care ribociclib (alone or as part of combination treatment)
• At least 18 years of age.
• No allergy to adhesive patches.
• Able to understand and willing to sign an IRB-approved written informed consent document.

Exclusion Criteria:

• Younger than 18 years of age
• Allergy to adhesive patches